New Versus Approved Methyl-aminolevulinate Photodynamic Therapy (MAL-PDT) Regime in Basal Cell Carcinoma (BCC)

NACompletedINTERVENTIONAL
Enrollment

277

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

October 31, 2017

Study Completion Date

October 31, 2017

Conditions
Skin NeoplasmsCarcinoma, Basal Cell
Interventions
DRUG

MAL-PDT re-treatment

a schedule of 1 single treatment of Metvix(R)-Photodynamic therapy with re-treatment of non-complete responders by 3 months

DRUG

usual MAL-PDT

schedule of 2 standard Metvix(R)- Photodynamic therapy treatment sessions 1 week apart.

Trial Locations (9)

Unknown

Dept Dermatology, Haukeland University Hospital, Bergen

Central Hospital Førde, Førde

Hudlegekontoret Lillehammer AS, Lillehammer

Akerskus Dermatological Centre, Lørenskog

Dept Dermatology, Oslo University Hospital, Oslo

Dept Surgery, Oslo University Hospital, Oslo

Hudlegen på Holtet, Oslo

Dept Dermato-Venereology, Stavanger University Hospital, Stavanger

Department of Cancer Research and Molecular Medicine, NTNU, Trondheim

All Listed Sponsors
collaborator

Akershus Dermatological Centre

UNKNOWN

collaborator

Helse Stavanger HF

OTHER_GOV

collaborator

Oslo University Hospital

OTHER

collaborator

Førde Central Hospital

OTHER

collaborator

Haukeland University Hospital

OTHER

collaborator

Hudlegekontoret Lillehammer

UNKNOWN

collaborator

Hudlegene på Holtet DA

UNKNOWN

lead

Norwegian University of Science and Technology

OTHER

NCT01482104 - New Versus Approved Methyl-aminolevulinate Photodynamic Therapy (MAL-PDT) Regime in Basal Cell Carcinoma (BCC) | Biotech Hunter | Biotech Hunter